Last €64.15 EUR
Change Today -0.15 / -0.23%
Volume 516.3K
MRK On Other Exchanges
As of 3:45 PM 08/21/14 All times are local (Market data is delayed by at least 15 minutes).

merck kgaa (MRK) Snapshot

Previous Close
Day High
Day Low
52 Week High
01/22/14 - €67.85
52 Week Low
09/12/13 - €55.20
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for MERCK KGAA (MRK)

Related News

No related news articles were found.

merck kgaa (MRK) Related Businessweek News

No Related Businessweek News Found

merck kgaa (MRK) Details

Merck KGaA, together with its subsidiaries, discovers, develops, manufactures, and markets products in the pharmaceutical and chemical sectors worldwide. It operates through four divisions: Merck Serono, Consumer Health, Performance Materials, and Merck Millipore. The Merck Serono division provides prescription medicines for the treatment of cancer, multiple sclerosis, infertility, growth disorders, cardiovascular, and metabolic diseases and allergies. The Consumer Health division offers over-the-counter pharmaceuticals for mobility and agility, everyday health protection, women’s and children’s health, and cough and cold under the Bion 3, Nasivin, Femibion, Seven Seas, Sangobion, Cebion, Sedalmerck, and Kytta brand names. The Performance Materials division provides specialty chemicals for use in various end products, such as liquid crystals for displays; LED materials for lighting, and OLED materials for lighting and displays; functional materials for solar panels and energy solutions; pigments, active ingredients, and fillers for cosmetics, food, and pharmaceutical products; and pigments and functional materials for coatings, printing, and plastics. The Merck Millipore division offers tools and laboratory chemicals that are used in the research, pharmaceutical and biotechnology industries, and analytical and clinical laboratories. The company was founded in 1668 and is headquartered in Darmstadt, Germany. Merck KGaA is a subsidiary of E. Merck KG.

39,230 Employees
Last Reported Date: 08/13/14
Founded in 1668

merck kgaa (MRK) Top Compensated Officers

Chairman of Executive Board
Total Annual Compensation: €5.4M
General Partner, Member of Executive Board an...
Total Annual Compensation: €4.5M
General Partner, Member of Executive Board an...
Total Annual Compensation: €4.5M
General Partner and Member of Executive Board
Total Annual Compensation: €3.7M
Compensation as of Fiscal Year 2013.

merck kgaa (MRK) Key Developments

Merck KGaA Reports Earnings Results for the Second Quarter Ended June 2014; Reaffirms Earnings Guidance for the Year 2014

Merck KGaA reported earnings results for the second quarter ended June 2014. For the quarter, the company reported revenues grew by 0.8% to EUR 2.863 billion. Net profit fell by 4.0% to EUR 303 million and underlying profit was down 3.3% at EUR 767 million. EBITDA pre, despite FX effects, despite the well-known loss of royalty income, showed a further improvement to EUR 846 million. EBIT is down by 5% to EUR 441 million. The reason for this decline is a onetime effect from the first-time consolidation of AZ the company had in the context of the purchase price allocation and inventory step-up of EUR 30 million, which has burned the cost of goods sold for the 2 months, May and June of the second quarter, and consequently also burned the gross profit margin, and actually was feeding through EBIT, net income and earnings per share for this EUR 30 million onetime effect is responsible for the EBIT and EPS reported decline. The company reaffirmed earnings guidance for the year 2014. The company expects overall sales would amount to EUR 10.9 billion to EUR 11.1 billion, operating profit would total EUR 3.3 billion to EUR 3.4 billion and EPS pre, after the share split, between EUR 4.50 and EUR 4.75. All numbers are including the AZ acquisition.

Merck KGaA Plans to Establish New Production Plants in Asian Region

Merck KGaA has planed to establish new production plants in the Association of Southeast Asian Nations (ASEAN) region, by the end of 2015.

Merck KGaA to Build USD 105 million Drug Manufacturing Plant in China

Merck KGaA has announced that it is planning to invest CNY 650 million (USD 105.0 million) in building a manufacturing facility in the city of Nantong in the Chinese province of Jiangsu. The facility will be used by the company's Merck Serono biopharmaceutical division to manufacture drugs for treating thyroid disorders, diabetes and cardiovascular disease, with all of these drugs having already been included in China's Essential Drug List (EDL). Production is expected to begin in 2017.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
MRK:GR €64.15 EUR -0.15

MRK Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Koninklijke DSM NV €49.51 EUR +0.74
PPG Industries Inc $205.08 USD +1.00
Seiko Epson Corp ¥5,270 JPY +130.00
Solvay SA €118.70 EUR +1.05
Sherwin-Williams Co/The $217.25 USD +2.21
View Industry Companies

Industry Analysis


Industry Average

Valuation MRK Industry Range
Price/Earnings 21.7x
Price/Sales 2.5x
Price/Book 2.4x
Price/Cash Flow 3.9x
TEV/Sales 0.2x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact MERCK KGAA, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at